The involvement of β2-glycoprotein I (β2-GPI) in human and murine atherosclerosis

被引:38
作者
George, J
Shoenfeld, Y
Harats, D [1 ]
机构
[1] Tel Aviv Univ, Sackler Fac Med, Chaim Sheba Med Ctr, Inst Lipid & Atherosclerosis Res, IL-52621 Tel Hashomer, Israel
[2] Tel Aviv Univ, Dept Med B, Tel Aviv, Israel
[3] Tel Aviv Univ, Autoimmune Dis Res Unit, Tel Aviv, Israel
关键词
atherosclerosis; oxLDL; beta 2-glycoprotein I; anti-phospholipid antibodies;
D O I
10.1006/jaut.1999.0288
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Atherosclerosis is a multifactorial process, the hallmark of which is fat deposition in the vessel wall. Autoimmune factors have recently been shown to play an important role in the initiation and progression of atherosclerosis; candidate autoantigens are oxidized lipids and heat shock proteins. beta 2-glycoprotein I (beta 2-GPI) is a highly glycosylated plasma protein that serves as a major antigenic target for autoimmune type antiphospholipid antibodies. Its major relevant property is binding to negatively charged phospholipids/surfaces. In the set of studies presented in this paper, we provide evidence pointing towards beta 2-GPI as an influential determinant in murine and human atherogenesis. Thus, immunization of transgenic atherosclerosis-prone mice (apolipoprotein E and low-density lipoprotein receptor knockouts) with human beta 2-GPI results in a brisk and sustained respective response that extends to cross-react with the 'self' murine beta 2-GPI. Atherosclerosis is accelerated in both strains concomitant with the infiltration of CD4 lymphocytes in the aortic sinus of the mice. When human plaques were studied, it was found that beta 2-GPI resides in the subendothelial regions and co-localizes with CD4 lymphocytes. Thus, the immune response towards beta 2-GPI may play an important role in atherogenesis, serving as a possible target for antigen specific therapies. (C) 1999 Academic Press.
引用
收藏
页码:57 / 60
页数:4
相关论文
共 36 条
[1]   Enhancement of atherosclerosis in beta-2-glycoprotein I-immunized apolipoprotein E-deficient mice [J].
Afek, A ;
George, J ;
Shoenfeld, Y ;
Gilburd, B ;
Levy, Y ;
Shaish, A ;
Keren, P ;
Janackovic, Z ;
Goldberg, I ;
Kopolovic, J ;
Harats, D .
PATHOBIOLOGY, 1999, 67 (01) :19-25
[2]  
BORBA EF, 1994, J RHEUMATOL, V21, P220
[3]   BETA-2-GLYCOPROTEIN-I IS A MAJOR PROTEIN ASSOCIATED WITH VERY RAPIDLY CLEARED LIPOSOMES IN-VIVO, SUGGESTING A SIGNIFICANT ROLE IN THE IMMUNE CLEARANCE OF NON-SELF PARTICLES [J].
CHONN, A ;
SEMPLE, SC ;
CULLIS, PR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (43) :25845-25849
[4]  
DelPapa N, 1997, ARTHRITIS RHEUM-US, V40, P551
[5]  
Ferro D, 1997, CIRCULATION, V95, P1425
[6]   ANTICARDIOLIPIN ANTIBODIES (ACA) DIRECTED NOT TO CARDIOLIPIN BUT TO A PLASMA-PROTEIN COFACTOR [J].
GALLI, M ;
COMFURIUS, P ;
MAASSEN, C ;
HEMKER, HC ;
DEBAETS, MH ;
VANBREDAVRIESMAN, PJC ;
BARBUI, T ;
ZWAAL, RFA ;
BEVERS, EM .
LANCET, 1990, 335 (8705) :1544-1547
[7]   Atherosclerosis-related markers in systemic lupus erythematosus patients: The role of humoral immunity in enhanced atherogenesis [J].
George, J ;
Harats, D ;
Gilburd, B ;
Levy, Y ;
Langevitz, P ;
Shoenfeld, Y .
LUPUS, 1999, 8 (03) :220-226
[8]   Differential effects of anti-β2-glycoprotein I antibodies on endothelial cells and on the manifestations of experimental antiphospholipid syndrome [J].
George, J ;
Blank, M ;
Levy, Y ;
Meroni, P ;
Damianovich, M ;
Tincani, A ;
Shoenfeld, Y .
CIRCULATION, 1998, 97 (09) :900-906
[9]   Atherosclerosis in LDL-receptor knockout mice is accelerated by immunization with anticardiolipin antibodies [J].
George, J ;
Afek, A ;
Gilburd, B ;
Levy, Y ;
Blank, M ;
Kopolovic, J ;
Harats, D ;
Shoenfeld, Y .
LUPUS, 1997, 6 (09) :723-729
[10]   Immunolocalization of β2 glycoprotein I (apolipoprotein H) to human atherosclerotic plaques -: Potential implications for lesion progression [J].
George, J ;
Harats, D ;
Gilburd, B ;
Afek, A ;
Levy, Y ;
Schneiderman, J ;
Barshack, I ;
Kopolovic, J ;
Shoenfeld, Y .
CIRCULATION, 1999, 99 (17) :2227-2230